These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 26075248)

  • 1. Early implementation of QbD in biopharmaceutical development: a practical example.
    Zurdo J; Arnell A; Obrezanova O; Smith N; Gómez de la Cuesta R; Gallagher TR; Michael R; Stallwood Y; Ekblad C; Abrahmsén L; Höidén-Guthenberg I
    Biomed Res Int; 2015; 2015():605427. PubMed ID: 26075248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An Intercompany Perspective on Biopharmaceutical Drug Product Robustness Studies.
    Morar-Mitrica S; Adams ML; Crotts G; Wurth C; Ihnat PM; Tabish T; Antochshuk V; DiLuzio W; Dix DB; Fernandez JE; Gupta K; Fleming MS; He B; Kranz JK; Liu D; Narasimhan C; Routhier E; Taylor KD; Truong N; Stokes ESE
    J Pharm Sci; 2018 Feb; 107(2):529-542. PubMed ID: 29074375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of Knowledge Management in Development and Lifecycle Management of Biopharmaceuticals.
    Rathore AS; Garcia-Aponte OF; Golabgir A; Vallejo-Diaz BM; Herwig C
    Pharm Res; 2017 Feb; 34(2):243-256. PubMed ID: 27785590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Developability assessment in pharmaceutical industry: An integrated group approach for selecting developable candidates.
    Saxena V; Panicucci R; Joshi Y; Garad S
    J Pharm Sci; 2009 Jun; 98(6):1962-79. PubMed ID: 18855914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quality cell therapy manufacturing by design.
    Lipsitz YY; Timmins NE; Zandstra PW
    Nat Biotechnol; 2016 Apr; 34(4):393-400. PubMed ID: 27054995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strategic funding priorities in the pharmaceutical sciences allied to Quality by Design (QbD) and Process Analytical Technology (PAT).
    Aksu B; De Beer T; Folestad S; Ketolainen J; Lindén H; Lopes JA; de Matas M; Oostra W; Rantanen J; Weimer M
    Eur J Pharm Sci; 2012 Sep; 47(2):402-5. PubMed ID: 22749874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medium term planning of biopharmaceutical manufacture using mathematical programming.
    Lakhdar K; Zhou Y; Savery J; Titchener-Hooker NJ; Papageorgiou LG
    Biotechnol Prog; 2005; 21(5):1478-89. PubMed ID: 16209554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biopharmaceutical Informatics: supporting biologic drug development via molecular modelling and informatics.
    Kumar S; Plotnikov NV; Rouse JC; Singh SK
    J Pharm Pharmacol; 2018 May; 70(5):595-608. PubMed ID: 28155992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HTS technologies in biopharmaceutical discovery.
    Wu G; Doberstein SK
    Drug Discov Today; 2006 Aug; 11(15-16):718-24. PubMed ID: 16846799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medium term planning of biopharmaceutical manufacture with uncertain fermentation titers.
    Lakhdar K; Farid SS; Titchener-Hooker NJ; Papageorgiou LG
    Biotechnol Prog; 2006; 22(6):1630-6. PubMed ID: 17137311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of assay technology as applied to safety assessment in reducing compound attrition in drug discovery.
    Thomas CE; Will Y
    Expert Opin Drug Discov; 2012 Feb; 7(2):109-22. PubMed ID: 22468913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-throughput process development for biopharmaceutical drug substances.
    Bhambure R; Kumar K; Rathore AS
    Trends Biotechnol; 2011 Mar; 29(3):127-35. PubMed ID: 21255855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quality by Design in Pharmaceuticals: A Review of its Impact on Regulatory Compliance and Product Quality.
    Nunavath RS; Singh MT; Jain A; Chakma M; Arivuselvam R; Azeeze MSTA
    Drug Res (Stuttg); 2024 Jan; 74(1):18-23. PubMed ID: 38134919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conference report: host cell protein workshop at the 2012 annual bioassay meeting of the biopharmaceutical emerging best practices association.
    Robinson CJ
    Bioanalysis; 2013 Feb; 5(4):407-10. PubMed ID: 23414373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biopharmaceutical drug discovery using novel protein scaffolds.
    Gill DS; Damle NK
    Curr Opin Biotechnol; 2006 Dec; 17(6):653-8. PubMed ID: 17055245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A software tool to assist business-process decision-making in the biopharmaceutical industry.
    Mustafa MA; Washbrook J; Lim AC; Zhou Y; Titchener-Hooker NJ; Morton P; Berezenko S; Farid SS
    Biotechnol Prog; 2004; 20(4):1096-102. PubMed ID: 15296435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Roadmap for implementation of quality by design (QbD) for biotechnology products.
    Rathore AS
    Trends Biotechnol; 2009 Sep; 27(9):546-53. PubMed ID: 19647883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploiting mAb structure characteristics for a directed QbD implementation in early process development.
    Karlberg M; von Stosch M; Glassey J
    Crit Rev Biotechnol; 2018 Sep; 38(6):957-970. PubMed ID: 29514519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving Drug Design: An Update on Recent Applications of Efficiency Metrics, Strategies for Replacing Problematic Elements, and Compounds in Nontraditional Drug Space.
    Meanwell NA
    Chem Res Toxicol; 2016 Apr; 29(4):564-616. PubMed ID: 26974882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How can we discover developable antibody-based biotherapeutics?
    Bauer J; Rajagopal N; Gupta P; Gupta P; Nixon AE; Kumar S
    Front Mol Biosci; 2023; 10():1221626. PubMed ID: 37609373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.